Investigational Site Number :8260001

Glasgow, Central Bedfordshire G12 0YN

0 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, Malignant Solid Tumor

Studies at this site

• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors — Completed